(SGRY) Surgery Partners - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US86881A1007
SGRY: Surgical, Ambulatory, Emergency, Urgent, Anesthesia
Surgery Partners, Inc. (NASDAQ:SGRY) operates a comprehensive network of surgical facilities and ancillary healthcare services across the United States. The company specializes in ambulatory surgery centers and surgical hospitals, focusing on non-emergency procedures across various specialties such as orthopedics, pain management, ophthalmology, gastroenterology, and general surgery. Additionally, Surgery Partners provides emergency department services and a range of ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. The company, founded in 2004 and headquartered in Brentwood, Tennessee, has established itself as a significant player in the outpatient surgical care sector, emphasizing cost-effective and specialized surgical services.
Over the next three months, Surgery Partners stock price is expected to face resistance at the SMA 50 level of 23.27, with potential support at the SMA 20 level of 21.53. The moderate ATR of 0.78 indicates manageable volatility. Fundamentally, the companys forward P/E of 25.13 reflects market expectations for future growth, despite the current negative RoE of -9.39, which may signal underlying financial challenges. Investors should monitor these technical and fundamental indicators for potential stock movement.
Additional Sources for SGRY Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SGRY Stock Overview
Market Cap in USD | 2,708m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception | 2015-10-01 |
SGRY Stock Ratings
Growth Rating | 8.04 |
Fundamental | 9.39 |
Dividend Rating | 0.0 |
Rel. Strength | -10.5 |
Analysts | 4.42/5 |
Fair Price Momentum | 20.00 USD |
Fair Price DCF | 28.53 USD |
SGRY Dividends
No Dividends PaidSGRY Growth Ratios
Growth Correlation 3m | -89.1% |
Growth Correlation 12m | -48.2% |
Growth Correlation 5y | -18.8% |
CAGR 5y | 15.59% |
CAGR/Max DD 5y | 0.22 |
Sharpe Ratio 12m | -1.21 |
Alpha | -19.06 |
Beta | 0.861 |
Volatility | 49.31% |
Current Volume | 784.5k |
Average Volume 20d | 878k |
As of April 30, 2025, the stock is trading at USD 22.33 with a total of 784,451 shares traded.
Over the past week, the price has changed by +8.87%, over one month by -5.98%, over three months by -13.28% and over the past year by -9.81%.
Neither. Based on ValueRay Fundamental Analyses, Surgery Partners is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 9.39 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SGRY as of April 2025 is 20.00. This means that SGRY is currently overvalued and has a potential downside of -10.43%.
Surgery Partners has received a consensus analysts rating of 4.42. Therefor, it is recommend to buy SGRY.
- Strong Buy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, SGRY Surgery Partners will be worth about 21.6 in April 2026. The stock is currently trading at 22.33. This means that the stock has a potential downside of -3.27%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 31.4 | 40.4% |
Analysts Target Price | 31.4 | 40.4% |
ValueRay Target Price | 21.6 | -3.3% |